XENCOR revises Ultomiris royalty forecast as licensee disputes US payments Mar 4, 2026 04:03PM
Truist Securities Reiterates Buy Rating on Xencor, Inc. (XNCR) Feb 4, 2026 09:52AM
Xencor outlines 2026 pipeline milestones for cancer, autoimmune drugs Jan 8, 2026 08:11AM
Biotechnology: Here are Piper Sandler's Top Picks and Focus Names for 2026 Dec 21, 2025 04:00AM
Xencor extends US patent term on Xtend antibodies through 2028 Dec 9, 2025 07:01AM


Nov 24, 2025 07:32AM Truist Securities Starts Xencor, Inc. (XNCR) at Buy
Nov 5, 2025 05:53PM Xencor (XNCR) Tops Q3 EPS by 61c
Oct 29, 2025 04:43AM Barclays Double Upgrades Xencor, Inc. (XNCR) to Overweight
Oct 27, 2025 09:00AM Xencor, Inc. (XNCR) PT Raised to $18 at RBC Capital
Oct 24, 2025 12:31PM Xencor reports 25% response rate in kidney cancer drug trial
Oct 15, 2025 07:09AM Cantor Fitzgerald Reiterates Overweight Rating on Xencor, Inc. (XNCR) Ahead of 10/24 Webcast
Oct 6, 2025 06:10AM Cantor Fitzgerald Starts Xencor, Inc. (XNCR) at Overweight
Sep 17, 2025 04:40AM Barclays Starts Xencor, Inc. (XNCR) at Underweight
Aug 21, 2025 05:16AM Xencor, Inc. (XNCR) PT Lowered to $15 at RBC Capital, 'We Think XNCR Pipeline Is Undervalued'
Aug 6, 2025 06:23PM Xencor (XNCR) Tops Q2 EPS by 31c
May 8, 2025 10:14AM Xencor, Inc. (XNCR) PT Lowered to $20 at JPMorgan
May 7, 2025 06:04PM Xencor (XNCR) Misses Q1 EPS by 4c
Apr 29, 2025 04:02PM Xencor (XNCR) Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942
Apr 21, 2025 06:38AM William Blair Starts Xencor, Inc. (XNCR) at Outperform
Mar 26, 2025 06:55AM Ocular Therapeutix (OCUL) Raymond James Adjusts Analyst Current Favorites List
Mar 13, 2025 04:02PM Xencor (XNCR) appoints Todd Simpson to Board
Feb 28, 2025 04:38AM Xencor (XNCR) Tops Q4 EPS by 19c ; Provides Outlook
Dec 2, 2024 03:43AM Piper Sandler Upgrades Xencor, Inc. (XNCR) to Overweight
Nov 7, 2024 10:19AM Xencor, Inc. (XNCR) PT Raised to $34 at BMO Capital
Nov 6, 2024 04:02PM Xencor (XNCR) Tops Q3 EPS by 27c ; Provides Outlook
Oct 10, 2024 08:09AM Xencor (XNCR) Presents Preclinical Data on XmAb942
Oct 4, 2024 08:01AM Xencor (XNCR) Announces Board Changes
Sep 26, 2024 06:22AM Xencor, Inc. (XNCR) PT Raised to $34 at RBC Capital
Sep 11, 2024 06:31AM Xencor (XNCR) Prices $175M Share and Warrant Offering at $18/sh
Sep 10, 2024 04:01PM Xencor (XNCR) Announces Proposed Share Offering
Sep 9, 2024 03:51PM JPMorgan on Xencor, Inc. (XNCR), Shares Up ~22.5%, 'offers advantages to move quickly in the space'
Sep 9, 2024 02:46PM BMO Capital Reiterates Outperform Rating on Xencor, Inc. (XNCR), PT $32, Shares Gain ~24% Today
Sep 9, 2024 02:45PM Barclays Reiterates Underweight Rating on Xencor, Inc. (XNCR), PT $22, Shares Gain ~24% Today
Sep 9, 2024 02:20PM TD Cowen Reiterates Buy Rating on Xencor, Inc. (XNCR)
Sep 9, 2024 07:31AM Xencor (XNCR) Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Aug 5, 2024 04:17PM Xencor (XNCR) Misses Q2 EPS by 25c, provides guidance
Jun 14, 2024 07:27AM Xencor, Inc. (XNCR) PT Lowered to $32 at BMO Capital
Jun 14, 2024 06:25AM Xencor, Inc. (XNCR) PT Lowered to $31 at RBC Capital
Jun 13, 2024 08:01AM Xencor (XNCR) Regains CD20 x CD3 Bispecific T-Cell Engager